28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
-
Among patients receiving mechanical ventilation: DEX group mortality rate was 29.0% compared to 40.7% in control group (RR 0.65, 95% CI: (0.51, 0.82), p<0.0001)
-
Among patients with other supplemental oxygen: DEX group mortality rate was 21.5% compared to 25% in control group (RR 0.80, 95% CI: (0.70, 0.92), p=0.002)
-
Among patients without any supplemental oxygen: DEX group mortality rate was 17.0% compared to 13.2% in control group (RR 1.22, 95% CI (0.93, 1.61), p=0.14)
-
Within the standard care group, 28-day mortality was highest for those on ventilation at randomization (40.7%), intermediate for oxygen only (25.0%), and lowest for no oxygen *13.2%)
-
A test for trend determined that DEX use significantly reduced mortality for longer illnesses
-
See table 2 node for more detail
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Table 1 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Table 2 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Figure 1 for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Figure 2. for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Duration of hospitalization results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Learn After
Table 2 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Figure 1 for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Figure 2. for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project